NCT00047346View on ClinicalTrials.gov

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

December 31, 2005

Conditions

Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer

Interventions

DRUG

erlotinib hydrochloride

Given PO

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00047346 - Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | Biotech Hunter | Biotech Hunter